Myriad Genetics, Inc. (NASDAQ:MYGN)‘s stock had its “hold” rating reiterated by analysts at Cowen and Company in a research note issued on Sunday. They presently have a $25.00 target price on the stock. Cowen and Company’s target price indicates a potential downside of 23.94% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. BidaskClub upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Monday, July 17th. Barclays PLC cut their price objective on shares of Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 9th. Deutsche Bank AG upgraded shares of Myriad Genetics from a “sell” rating to a “hold” rating and cut their price objective for the company from $27.86 to $15.00 in a research report on Friday, August 18th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $23.00 price objective (up from $21.00) on shares of Myriad Genetics in a research report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $21.22.

Myriad Genetics (MYGN) opened at 32.87 on Friday. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $33.42. The stock has a 50 day moving average of $28.75 and a 200 day moving average of $23.22. The firm has a market capitalization of $2.25 billion, a PE ratio of 103.04 and a beta of 0.26.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The company had revenue of $200.50 million during the quarter, compared to analyst estimates of $193.71 million. During the same period last year, the business earned $0.36 earnings per share. Myriad Genetics’s revenue was up 7.5% compared to the same quarter last year. On average, equities analysts predict that Myriad Genetics will post $1.02 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/17/myriad-genetics-mygn-hold-rating-reaffirmed-at-cowen-and-company.html.

In related news, Director John T. Henderson sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $30.30, for a total value of $909,000.00. Following the sale, the director now directly owns 52,524 shares of the company’s stock, valued at $1,591,477.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in MYGN. BlackRock Inc. raised its stake in Myriad Genetics by 168,335.7% in the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock valued at $183,203,000 after purchasing an additional 9,536,219 shares in the last quarter. Thrivent Financial For Lutherans raised its stake in Myriad Genetics by 7,026.7% in the second quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock valued at $70,862,000 after purchasing an additional 2,703,860 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Myriad Genetics by 59.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,642,820 shares of the company’s stock valued at $50,742,000 after purchasing an additional 987,966 shares in the last quarter. Vanguard Group Inc. raised its stake in Myriad Genetics by 16.8% in the first quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock valued at $120,020,000 after purchasing an additional 897,287 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Myriad Genetics by 131.2% in the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock valued at $17,632,000 after purchasing an additional 521,146 shares in the last quarter.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.